IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease

Femoropopliteal Disease Clinical Trial

— ICARUS  

Official title:

IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease (ICARUS Trial); A Feasibility Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05805280
• Other study ID #: 2019-1514
• Status: Recruiting
• Phase: N/A
• Start date: November 27, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: Asan Medical Center
• Contact: Ji Sue Hong, RN
• Phone: 82 2-2045-3798
• Email: sue5165[@]naver.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objectives: 1) To evaluate the feasibility of using intravascular ultrasound to assess lesion morphology, select an appropriate stent size and landing zone 2) To compare the primary patency rates after intra vascular imaging-guided versus angiography-guided stent implantation for the treatment of fermoropopliteal artery segment lesions. Hypothesis: One of the key determinants of the device failure is inappropriate landing zone, selection of smaller stent relative to the reference vessel diameter, and lack of high-pressure post-dilatation in a necessary post-stent segment. Therefore, intravascular ultrasound-guided selection of appropriate landing zone, stent size and balloon size for high pressure post-dilation may maximize the benefits of stent use and improve patency duration. the investigators hypothesize that intravascular ultrasound-guided stent implantation is superior to angiography-guided stent implantation with respect to 12 months primary patency in patients with significant femoropopliteal disease

Description:

This is a prospective, open-label, randomized comparison feasibility trial involving patients with significant femoropopliteal disease who are undergoing drug-eluting stent (paclitaxel-eluting, durable-polymer-coated Eluvia stent) implantation. Patients with symptoms attributable to limb ischemia are eligible for enrollment if the culprit lesions are suitable for stent implantation based on angiographic findings. The detailed information for inclusion and exclusion criteria is described below in session 7. Patients meeting inclusion criteria without any exclusion criteria will be randomized to either intravascular ultrasound-guided or angiography-guided group immediately before the endovascular intervention. In the intravascular ultrasound-guided group, intravascular ultrasound will be either automatically (1 mm/sec) or manually (5-10 mm/sec) pulled back at a constant speed according to the lesion length. Stent size and length are selected by information acquired from on-line intravascular ultrasound examination, and adjunct high-pressure dilation is performed to achieve stent optimization based on the intravascular ultrasound finding. For the selection of the landing zone and stent length, intravascular ultrasound and fluoroscopy images should be recorded simultaneously to link intravascular ultrasound images with location preferably using a ruler. For the selection of stent size and assessment of stent optimization, external elastic membrane area (EEM) before ballooning and minimal stent area (MSA) (i.e, the smallest cross-sectional area within the stent) after post-dilation are assessed. intravascular ultrasound is used at any step of the procedure before, during, or after stenting. However, image examination is mandatory before and after stenting. In the angiography-guided group, stent size and length are chosen by visual estimation, and adjunctive high-pressure dilation is performed if an optimal result, defined as angiographic residual diameter stenosis of less than 30% by visual estimation and the absence of angiographically detected dissection, was not achieved. Stent size is chosen at the operator's discretion in both groups, with diameters 1 or 2 mm larger than the reference diameter assessed either by intravascular ultrasound or visual estimation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

• Men or women at least 20 years up to 85 years of age
• Intermittent claudication or tissue loss suitable for elective endovascular intervention (Rutherford category 2,3,4, or 5)
• Significant native superficial femoral or proximal popliteal artery lesions suitable for stent implantation. Restenotic lesions can be enrolled at least 12-month after the index procedure uding plain balloon or drug-coated balloon.
• Total lesion length of 30 to 220 mm
• Reference vessel diameter of 4 - 6 mm
• The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion Criteria:

• Existence of a stent in the target vessel
• Previous use of atherectomy device in the target vessel
• Use of drug-coated balloon in the target vessel within 12-month
• Untreatable significant stenosis or occlusion (diameter stenosis =70%) in all 3 infrapopliteal arteries (patient can be enrolled if at least 1 patent outflow artery to the ankle (diameter stenosis <50%) can be achieved by treatment during the index procedure)
• A known intolerance or contraindication to antiplatelet drugs (aspirin or clopidogrel)
• Unwillingness or inability to comply with the procedures described in this protocol.

Related Conditions & MeSH terms

• Femoropopliteal Disease

Intervention

Device:
• intravascular ultrasound-guided group
intravascular ultrasound use
• angiography-guided group
angiography-guided use

Locations

Country	Name	City	State
Korea, Republic of	Inje University Busan Paik Hospital	Busan
Korea, Republic of	Veterans Hospital	Daegu
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Kangbuk Samsung Hospital	Seoul
Korea, Republic of	Konkuk University Medical Center	Seoul
Korea, Republic of	Severance Cardiovascular Hospital	Seoul
Korea, Republic of	Veterans Health Service Medical Center	Seoul
Korea, Republic of	Ajou University Medical Center	Suwon

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	patency at 12 months after treatment	peak systolic velocity ratio 2.4 or lower as assessed by the duplex ultrasound, in the absence of clinically driven target lesion revascularization or bypass of the target lesion.	12 month after randomization
Primary	Number of procedure related death	procedure related death through 30 days post-procedure	30 Days post procedure
Primary	Number of major amputation of the target limb or target-lesion revascularization	major amputation of the target limb through 12 months, or target-lesion revascularization through 12 months	12 month after randomization
Secondary	technical success	deployment of the stent to the target lesion to achieve residual angiographic stenosis =30%	within 24 hours
Secondary	procedural success	technical success without major adverse events	within 24 hours
Secondary	Rutherford category score	Stage 0 - Asymptomatic; Stage 1 - Mild claudication; Stage 2 - Moderate claudication; Stage 3 - Severe claudication; Stage 4 - Rest pain; Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot; Stage 6 - Severe ischemic ulcers or frank gangrene	12 month after randomization